You already said, you won't touch stocks with no/little revenue.
How could NHL trap you?
PCK, $270m, with 72k revenue for last quarter, CE mark, but not FDA approved yet.
NHL, $38m, with little revenue, received FDA approval, CE mark, TGA and included in NDIS reimbursement system.
NHL's peer, Akili, still developing ADHD app, still waiting for FDA approval, sold partial rights (in Japan & Taiwan) for a whopping USD$125m (USD$20m cash + USD$105m milestone payments).
Do you really reckon NHL's $38m valuation is HYPED?
You already said, you won't touch stocks with no/little revenue....
-
- There are more pages in this discussion • 6,576 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
